These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10651656)

  • 1. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet.
    Wilding IR; Kenyon CJ; Hooper G
    Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects.
    Wilding IR; Behrens C; Tardif SJ; Wray H; Bias P; Albrecht W
    Aliment Pharmacol Ther; 2003 May; 17(9):1153-62. PubMed ID: 12752352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
    Karkossa F; Klein S
    J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
    Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers.
    Brunner M; Greinwald R; Kletter K; Kvaternik H; Corrado ME; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2003 May; 17(9):1163-9. PubMed ID: 12752353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.
    Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR
    J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy.
    Brown J; Haines S; Wilding IR
    Aliment Pharmacol Ther; 1997 Aug; 11(4):685-91. PubMed ID: 9305476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
    Schellekens RC; Stuurman FE; van der Weert FH; Kosterink JG; Frijlink HW
    Eur J Pharm Sci; 2007 Jan; 30(1):15-20. PubMed ID: 17085024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.
    Brunner M; Assandri R; Kletter K; Tschurlovits M; Corrado ME; Villa R; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2003 Feb; 17(3):395-402. PubMed ID: 12562452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
    Sandborn WJ; Hanauer SB
    Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver and gut mucosa acetylation of mesalazine in healthy volunteers.
    Vree TB; Dammers E; Exler PS; Sörgel F; Bondesen S; Maes RA
    Int J Clin Pharmacol Ther; 2000 Nov; 38(11):514-22. PubMed ID: 11097143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A; Hatton GB; Merchant HA; Basit AW
    Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of controlled release mesalazine (5-ASA) preparations.
    Rasmussen SN
    J Gastroenterol; 1995 Nov; 30 Suppl 8():112-4. PubMed ID: 8563869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.